This highlights the potential of tumor cell-intrinsic PD-1 expression as a novel predictive biomarker for the efficacy of anti-PD-1 therapy, offering a new therapeutic avenue for treating NSCLC [255]. The gene discussed is PDCD1; the disease is neoplasm.